Beta Bionics, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Beta Bionics, Inc. (BBNX) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$5.44 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-07-29
- Beta Bionics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was -$222.00K, a 108.15% decline year-over-year.
- Beta Bionics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$5.22M.
- Beta Bionics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $5.86M, a 64.16% increase year-over-year.
- Beta Bionics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $4.12M, a 242.92% increase year-over-year.
- Beta Bionics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $7.42M, a 8.57% increase from fiscal 2024.
- Beta Bionics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $6.84M, a 274.68% increase from fiscal 2023.
- Beta Bionics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $1.82M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$222.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$5.44M 10-Q · filed 2026-07-29 | $420.00K derived: sum of 3 quarters · filed 2026-07-29 | $4.54M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | -$5.22M 10-Q · filed 2026-04-21 | $642.00K derived: sum of 2 quarters · filed 2026-04-21 | $4.76M derived: sum of 3 quarters · filed 2026-04-21 | $7.48M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $5.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $9.97M derived: sum of 2 quarters · filed 2026-02-24 | $12.70M derived: sum of 3 quarters · filed 2026-07-29 | $7.42M 10-K · filed 2026-02-24 |
| 2025-09-30 | $4.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $6.84M derived: sum of 2 quarters · filed 2026-07-29 | $1.56M 10-Q · filed 2025-10-28 | $5.13M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $2.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$2.55M 10-Q · filed 2026-07-29 | $1.02M derived: sum of 3 quarters · filed 2026-07-29 | $2.22M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | -$5.27M 10-Q · filed 2026-04-21 | -$1.70M derived: sum of 2 quarters · filed 2026-04-21 | -$504.00K derived: sum of 3 quarters · filed 2026-04-21 | $1.80M derived: sum of 4 quarters · filed 2026-04-21 |
| 2024-12-31 | $3.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $4.77M derived: sum of 2 quarters · filed 2026-02-24 | $7.07M derived: sum of 3 quarters · filed 2026-02-24 | $6.84M 10-K · filed 2026-02-24 |
| 2024-09-30 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $3.50M derived: sum of 2 quarters · filed 2025-10-28 | $3.27M 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $2.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $2.07M 10-Q · filed 2025-07-29 | ||
| 2024-03-31 | -$231.00K 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $1.82M 10-K/A · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |